of PC would potentially be thrombogenic. sEPCR levels suggested under genetic control. There are 13 polymorphisms in EPCR gene which are in complete linkage disequilibrium; these defined 3 haplotypes, 1 of which (A3) was strongly associated with high sEPCR levels. However A3 haplotype of EPCR is a risk factor for DVT remains controversial. The aim of the study is to investigate the role of A-3 Haplotype in the development of DVT. Methods: One hundred consecutive patients (M: F=62:48) with idiopathic DVT and equal number of age and sex matched healthy controls were the study subjects. All study subjects were typed for A3 haplotype tagging SNP(A6936G) using PCR-RFLP. Results: The A3 haplotype tagging snp (A6936G) showing its allelic association with DVT (P=0.04, γ2 = 3.93, O.R. = 3.93). Comment: However a larger sample size representative of the diverse Indian population along with EPCR levels would be required to confirm this finding. doi:10.1016/j.thromres.2012.08.123 C0169 Cave thrombosis in Behçet's disease: A report of 29 cases Imed Ben Ghorbel, Nabil Belfeki, Fatma Said, Thouraya Ben Salem, Mounir Lamloum, Amel Braham, Monia Khanfir, Amira Hamzaoui, Habib Houman La Rabta Hospital, Internal Medecine - Bab Saadoun, Tunisia Background: Venous thrombosis is common in Behçet's disease (BD). All veins could be involved. The aim is to study demographic and clinical features of patients having BD with vena cava thrombosis (VCT). Methods: Patients followed in our internal medicine centre for BD (fulfilled the criteria of the ISG of BD) were retrospectively studied. Only patients with vena cava thrombosis were ruled. Doppler ultrasound and angiography were applied to confirm venous thrombosis. Results: 29 among 430 patients with BD, had vena cava thrombosis (6.7%). They were all male. Their mean age at the beginning of the disease was 25.65 (range 13 to 38) and was 32.34 years (extreme 18 to 48 years) at the time of vena cava thrombosis' diagnosis. The average delay to vena cava diagnosis from the BD diagnosis was 7 years. 18 patients had superior vena cava thrombosis and 16 had inferior vena cava thrombosis. The 2 localizations occurred in the same patient in 5 cases. None of the patients had an isolated vena cava thrombosis. Superior vena cava thrombosis was often associated to jugular thrombosis (12 cases, 66.6%). Inferior vena cava thrombosis was associated to lower limbs' venous thrombosis in 13 cases (81.25%) and to hepatic veins thrombosis in 6 patients. Comparison between patients with and without VCT showed that lower limbs' thrombosis were significantly more frequent in the first group. Comment: Frequency of vena cava thrombosis in our study is com- parable to those of European studies. They are usually associated with other thrombosis. BD remains a main etiology of vena cava thrombosis. doi:10.1016/j.thromres.2012.08.124 C0172 Unusual complication in Wegener's granulomatosis : Deep venous thrombosis. About four cases Imed Ben Ghorbel, Nabil Belfeki, Amel Braham, Mounir Lamloum, Thouraya Ben Salem, Monia Khanfir, Amira Hamzaoui, Habib Houman La Rabta Hospital, Internal Medecine - Bab Saadoun, Tunisia Background: Wegener's granulomatosis (WG) is a multiorgan system disease of unknown etiology characterized by granulomatous inflammation, tissue necrosis and variable degrees of vasculitis in small- and medium-sized blood vessels. Venous thrombosis is a rare event in WG. Methods: We report hereby four cases and discuss the mechanisms concerned by this unusual complication. Results: Four patients (3 males and 1 female) with a mean age of 42.5 years (26/55) were diagnosed with WG according to the American College of Rheumatology (ACR) criteria. WG was revealed in three cases by an unusual presentation : an orbital tumor, mucocutaneous ulcers, and a retroperitoneal fibrosis. All patients presented a glomerulonephritis complicated by a nephrotic syn- drome in 2 cases and renal failure in 1 case. Two cases of pulmonary involvement were revealed respectively by an alveolar hemorrhage and nodular lesions. Venous thrombosis occured within an average of 6 months (2/24). Venous thrombosis was deep in all cases and complicated by a fatal pulmonary embolism in one case. Positive c- ANCA was present in all cases and we noticed hypereosinophilia in one case. Thrombophilic markers (protein C, S, acquired activated protein C, prothrombin, homocysteinemia, and antiphospholipides antibodies) were realized in two cases and were negative in both. All patients were treated by corticosteroids at a dose of 1 mg/kg/day associated to monthly pulses of cyclophosphamide at a dose of 0.5 g/m2. Remission was almost complete in all patients. Comment: Venous thrombosis in WG is a multifactorial event often associated to a nephrotic syndrome. It is a serious complication that necessitates prophylactic measures. doi:10.1016/j.thromres.2012.08.125 C0179 Deep vein thrombosis of upper extremities(UEDVT): A tertiary center's experience Anastasia Banti 1 , Emmanouil Papadakis 1 , Vassilios Papadopoulos 1 , Konstantinos Loukidis 1 , Dionysia Theocharidou 2 , Smaragda Efraimidou 1 , Anna Karagianni 1 , Vaia Papageorgiou 1 , Vassiliki Pissanidou 1 , Parthena Kapali 1 , Anna Kioumi 1 1 Papageorgiou Hospital, Hemostasis Unit, Greece; 2 Papageorgiou Hospital, Microbiology Department, Greece Background: Upper extremities deep vein thrombosis (UEDVT), although less common than lower extremities DVT (4-12%), is related to significant morbidity and mortality (PE 12%, PTS 13%, mortality 15- 50%). It occurs mainly in older patients with comorbidities. Primary UEDVT is related to anatomic abnormalities of thoracic and axillary cavities. Causes of UEDVT include trauma, infection, intravenous drug use, septic vein thrombosis, congestive heart failure, central venous catheters, cancer, strenuous exercise and hypercoagulable states. Due to lack of randomized trials, there is no consensus over the duration of anticoagulant treatment, which is generally suggested to be the same as for lower extremities DVT. Methods: We present our center's experience on UEDVT. We performed thrombophilic analysis to all of them who had no apparent cause for thrombosis. A total of 13 patients (7 male) were referred to our Hemostasis Unit. Nine of them had underlying thrombophilia (FVLeiden:6, FII G20210A:2, elevated FVIII:1), and 7/ 9 had additional risk factors (transient of permanent) without coexisting medical conditions. One of the remaining 4 patients, suffered from non-Hodgkin lymphoma and 2 patients had no thrombophilia. Regarding relapses, 4/13 had at least one more DVT event of upper or lower extremities. All patients received anticoag- ulants for at least 6 months and 5 of them are under continuous Abstracts / Thrombosis Research 130 (2012) S100–S202 S149